- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02862340
Study of the Involvement of 15q11 - q13 Chromosome Region and CYFIP1 Gene in Autism. Attempt a Genotype-phenotype Correlation
Autism, ranked among the '' pervasive developmental disorders' (ASD), is characterized by disturbances in the areas of reciprocal social interaction, communication and behavior, interests and activities restricted, repetitive. Various studies indicate that autistic disorder is subjected to a genetic predisposition, most likely polygenic and heterogeneous. However, no major gene responsible for this disorder has yet been identified. Given the link between the Fragile X syndrome (the most common form of mental retardation (MR) hereditary) and autistic behavior, it seems interesting to look, also, a possible link to the molecular level. Among the proteins interacting with FMRP (absent protein in fragile X patients), the investigators were interested to CYFIP1, protein encoded by the gene CYFIP1 appears to be a good candidate gene involved in the RM and autism by its chromosomal position and function. As FMR1, CYFIP1 is expressed in the brain cortex, hippocampus and Purkinje cells of the cerebellum. This protein co-localizes and interacts with Rac and FMRP, which are both involved in neurogenesis and cognitive development. In humans, the gene encoding CYFIP1 is located in the 15q11-q13. Now, the only autosomal abnormalities most frequently observed in autism are those involving the proximal 15q region, including duplications or 15q11-q13 triplications interstitial, of maternal origin.
These data suggest that an / or more autism genes responsible are probably present in the 15q11-q13 chromosomal region, although no gene has yet been identified. Thus, the study of the role of CYFIP1 gene in patients with autism spectrum disorders would most likely contributory.
The investigators wish to study the involvement of the 15q11-q13 chromosomal region and CYFIP1 gene in autistic disorder in a hundred patients from the Autism Resource Centre (ARC) Nice PACA antenna, over a two year period.
The diagnosis and assessment report of children likely to be included in this study will be conducted at ARC Nice. Balance sheets are made according to the recommendations of the High Authority of Health for diagnosis of infantile autism and PDD. These children are then sent to the Genetic Consultation Nice Hospital where an analysis of the background and a specific morphological examination will be realized..
Study Overview
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Nice, France
- CHU de Nice
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject unadopted 4 to 18 years
- Subject completing the autism spectrum disorder criteria development by diagnostic grid ICD10 recognized by the international community child psychiatry. The ADI-R test is always associated.
- Subject has at least one of the following abnormalities:
Mental retardation, Anomaly morphological examination (abnormal weight and height growth and / or head circumference, abnormal ends, dysmorphic ...) Malformation (s) visceral (s) Behavioural disorders other than autistic disorder (aggression, sleep disorders ...) Abnormal neurological examination and brain imaging, Family history of autism and / or mental retardation.
- Parents of the subject and topics affiliated to a social security scheme
Exclusion Criteria:
- Etiologie de la pathologie autistique connue (Syndrome de Rett, Xfra…)
- Absence de consentement éclairé des patients et des représentants de l'autorité parentale
- Parents sous tutelle ou curatelle
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Autistic disorder
Children over 4 years with an autistic disorder of unknown etiology with the techniques currently available and accessible in routine diagnostics.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
presence or absence of abnormality in 15q11q13 gene
Time Frame: At the inclusion
|
Testing a candidate gene in a chromosomal region known to be involved in autism
|
At the inclusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
phenotype
Time Frame: At the inclusion
|
Syndromic or specific behavioral phenotypes corresponding to the identified molecular abnormalities
|
At the inclusion
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 07-PP-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autistic Disorder
-
Hadassah Medical OrganizationTerminated
-
Mahidol UniversityCompleted
-
University of JazanCompletedAutistic Spectrum DisorderSaudi Arabia
-
Assistance Publique - Hôpitaux de ParisHopital Universitaire Robert-Debre; Henri Mondor University Hospital; Fondation... and other collaboratorsCompleted
-
Fundatia Bio-ForumSpitalul AngiomedicaCompletedAutistic Spectrum DisorderRomania
-
Sutter Medical FoundationCompleted
-
Stanford UniversityCalifornia Department of Developmental ServicesRecruitingAutism Spectrum Disorder | Autistic Disorder | Autism | Autism Spectrum Disorders | Autistic Disorders Spectrum | Autistic Spectrum Disorder | Autistic Spectrum DisordersUnited States
-
Hospital Parc Taulí, SabadellUnknownSexual Behavior | Adolescent Development | Autistic Disorders Spectrum | Sexual InadequacySpain
-
Sheba Medical CenterRecruitingAutistic Spectrum DisorderIsrael
-
Université de Reims Champagne-ArdenneNot yet recruitingImpact of Mixed Reality Training on Motor Skills in Children With Autistic Spectrum Disorder (RAMAu)Autistic Spectrum Disorder
Clinical Trials on Genetic test
-
Augusta UniversityRecruitingOvarian Cancer | Endometrial Cancer | Peritoneal CancerUnited States
-
Hospital Universitari Vall d'Hebron Research InstituteCompleted
-
Second Affiliated Hospital, School of Medicine,...CompletedWilson Disease | Generalized EpilepsyChina
-
Mayo ClinicNational Cancer Institute (NCI)CompletedMalignant Solid Neoplasm | Breast Carcinoma | Digestive System Neoplasm | Skin Carcinoma | Malignant Female Reproductive System Neoplasm | Metastatic Malignant Neoplasm of Unknown Primary | Malignant Head and Neck Neoplasm | Malignant Brain Neoplasm | Malignant Central Nervous System Neoplasm | Malignant... and other conditionsUnited States
-
Duke UniversityGenentech, Inc.TerminatedPrimary Open Angle Glaucoma | Glaucoma | Glaucoma, SuspectUnited States
-
Samsung Medical CenterRecruiting
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingLynch Syndrome | Relatives | Endometrial Carcinoma | Endometrial AdenocarcinomaUnited States
-
Mayo ClinicEnrolling by invitationRare Diseases | Undiagnosed DiseaseUnited States
-
Polish Mother Memorial Hospital Research InstituteActive, not recruitingRecurrent Patellar Dislocation | Ligament; LaxityPoland
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); Oregon Health and Science UniversityRecruitingMalignant Solid Neoplasm | Lynch Syndrome | Hematopoietic and Lymphoid System Neoplasm | Breast Ductal Carcinoma In Situ | Hereditary Neoplastic Syndrome | BRCA1/2-Associated Hereditary Breast and Ovarian Cancer SyndromeUnited States